Harvard Bioscience (NASDAQ:HBIO) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Harvard Bioscience (NASDAQ:HBIO) issued its quarterly earnings results on Monday. The medical instruments supplier reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02, Zacks reports. Harvard Bioscience had a negative net margin of 14.57% and a negative return on equity of 4.64%. Harvard Bioscience updated its Q2 2025 guidance to EPS.

Harvard Bioscience Price Performance

NASDAQ HBIO opened at $0.32 on Monday. The company has a market cap of $14.15 million, a PE ratio of -0.97 and a beta of 1.44. Harvard Bioscience has a 52 week low of $0.29 and a 52 week high of $3.60. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The firm’s 50-day simple moving average is $0.50 and its two-hundred day simple moving average is $1.43.

Institutional Investors Weigh In On Harvard Bioscience

A hedge fund recently raised its stake in Harvard Bioscience stock. Bank of America Corp DE increased its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 44.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,883 shares of the medical instruments supplier’s stock after purchasing an additional 11,948 shares during the period. Bank of America Corp DE owned approximately 0.09% of Harvard Bioscience worth $82,000 as of its most recent SEC filing. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Benchmark cut their price target on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a report on Monday, March 24th. KeyCorp reissued a “sector weight” rating on shares of Harvard Bioscience in a report on Wednesday, April 9th. Finally, StockNews.com assumed coverage on shares of Harvard Bioscience in a report on Tuesday, May 6th. They issued a “hold” rating on the stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.